Alopecia universalis and type 1 diabetes mellitus both successfully controlled with baricitinib in a patient with autoimmune polyglandular syndrome type 3A
Ayane Goto
Department of Dermatology, Graduate School of Medicine, Nagoya University, Nagoya, Aichi, Japan
Search for more papers by this authorCorresponding Author
Yuta Yamashita
Department of Dermatology, Graduate School of Medicine, Nagoya University, Nagoya, Aichi, Japan
Correspondence
Yuta Yamashita, Department of Dermatology, Graduate School of Medicine, Nagoya University, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan.
Email: [email protected]
Search for more papers by this authorJun Yuasa
Department of Diabetology, Yokkaichi Municipal Hospital, Yokkaichi, Mie, Japan
Search for more papers by this authorSatoshi Kamiya
Department of Dermatology, Graduate School of Medicine, Nagoya University, Nagoya, Aichi, Japan
Search for more papers by this authorNorika Akashi
Department of Dermatology, Graduate School of Medicine, Nagoya University, Nagoya, Aichi, Japan
Search for more papers by this authorHaruka Koizumi
Department of Dermatology, Graduate School of Medicine, Nagoya University, Nagoya, Aichi, Japan
Search for more papers by this authorMariko Ogawa-Momohara
Department of Dermatology, Graduate School of Medicine, Nagoya University, Nagoya, Aichi, Japan
Search for more papers by this authorTakuya Takeichi
Department of Dermatology, Graduate School of Medicine, Nagoya University, Nagoya, Aichi, Japan
Search for more papers by this authorYoshinao Muro
Department of Dermatology, Graduate School of Medicine, Nagoya University, Nagoya, Aichi, Japan
Search for more papers by this authorMasashi Akiyama
Department of Dermatology, Graduate School of Medicine, Nagoya University, Nagoya, Aichi, Japan
Search for more papers by this authorAyane Goto
Department of Dermatology, Graduate School of Medicine, Nagoya University, Nagoya, Aichi, Japan
Search for more papers by this authorCorresponding Author
Yuta Yamashita
Department of Dermatology, Graduate School of Medicine, Nagoya University, Nagoya, Aichi, Japan
Correspondence
Yuta Yamashita, Department of Dermatology, Graduate School of Medicine, Nagoya University, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan.
Email: [email protected]
Search for more papers by this authorJun Yuasa
Department of Diabetology, Yokkaichi Municipal Hospital, Yokkaichi, Mie, Japan
Search for more papers by this authorSatoshi Kamiya
Department of Dermatology, Graduate School of Medicine, Nagoya University, Nagoya, Aichi, Japan
Search for more papers by this authorNorika Akashi
Department of Dermatology, Graduate School of Medicine, Nagoya University, Nagoya, Aichi, Japan
Search for more papers by this authorHaruka Koizumi
Department of Dermatology, Graduate School of Medicine, Nagoya University, Nagoya, Aichi, Japan
Search for more papers by this authorMariko Ogawa-Momohara
Department of Dermatology, Graduate School of Medicine, Nagoya University, Nagoya, Aichi, Japan
Search for more papers by this authorTakuya Takeichi
Department of Dermatology, Graduate School of Medicine, Nagoya University, Nagoya, Aichi, Japan
Search for more papers by this authorYoshinao Muro
Department of Dermatology, Graduate School of Medicine, Nagoya University, Nagoya, Aichi, Japan
Search for more papers by this authorMasashi Akiyama
Department of Dermatology, Graduate School of Medicine, Nagoya University, Nagoya, Aichi, Japan
Search for more papers by this author
REFERENCES
- 1Neufeld M, Maclaren N, Blizzard R. Autoimmune polyglandular syndromes. Pediatr Ann. 1980; 9: 154–162.
- 2Betterle C, Garelli S, Coco G, Burra P. A rare combination of type 3 autoimmune polyendocrine syndrome (APS-3) or multiple autoimmune syndrome (MAS-3). Auto Immun Highlights. 2014; 5: 27–31.
- 3Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines–part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004; 51: 440–447.
- 4Freitas E, Guttman-Yassky E, Torres T. Baricitinib for the treatment of alopecia areata. Drugs. 2023; 83: 761–770.
- 5Waibel M, Wentworth JM, So M, Couper JJ, Cameron FJ, MacIsaac RJ, et al. Baricitinib and β-cell function in patients with new-onset type 1 diabetes. N Engl J Med. 2023; 389: 2140–2150.
